论文部分内容阅读
目的:探讨膀胱癌组织中PCNA、c-erbB2、bcl-2和P53蛋白表达与临床病理的关系。方法:检测58例膀胱癌和正常黏膜各作为对照。用免疫组织化学法检测PCNA、c-erbB2、bcl-2和P53蛋白表达结果:膀胱癌组织中PCNA、c-erbB2、bcl-2、P53阳性率显著高于癌旁组织。阳性率分别为74.1%、60.3%、62.1%、51.7%。c-erbB2、bcl-2与PCNA的阳性表达呈正相关,c-erbB2、bcl-2与p53的阳性表达呈负相关。PCNA、c-erbB2、bcl-2、p53同时阳性集中在WHO病理分级G2、G3中。结论:PCNA、c-erbB2、bcl-2和P53蛋白过度表达与临床病理分期关系密切,上述指标的联合检测可以作为临床早期诊断膀胱癌及其了解预后的重要参考指标。
Objective: To investigate the relationship between the expression of PCNA, c-erbB2, bcl-2 and P53 in bladder cancer and clinicopathological features. Methods: 58 cases of bladder cancer and normal mucosa were detected as control. The expressions of PCNA, c-erbB2, bcl-2 and P53 were detected by immunohistochemistry. The positive rates of PCNA, c-erbB2, bcl-2 and P53 in bladder cancer tissues were significantly higher than those in paracancerous tissues. The positive rates were 74.1%, 60.3%, 62.1% and 51.7% respectively. The positive expression of c-erbB2 and bcl-2 was positively correlated with the expression of PCNA. The positive expression of c-erbB2 and bcl-2 was negatively correlated with the expression of p53. PCNA, c-erbB2, bcl-2, p53 simultaneously positive in the WHO pathological grading G2, G3. Conclusion: The overexpression of PCNA, c-erbB2, bcl-2 and P53 is closely related to the clinicopathological stage. The combined detection of the above indexes can be used as an important reference for early diagnosis of bladder cancer and its prognosis.